Publications scientifiques Bordet

Publications scientifiques Bordet

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Blanc J, Carnot A, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaudenarde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Blanc J, Carnot A, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaudenarde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
Erasme hospital

Hôpital Erasme

Consultez toutes les publications scientifiques d'Erasmus

Publications scientifiques d'Erasmus
Huderf hospital

Hôpital pédiatrique Reine Fabiola

Consultez toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola

Publications scientifiques de l'Hôpital pour enfants Reine Fabiola
Bordet hospital

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet

Publications scientifiques de Jules Bordet